Navigation Links
Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
Date:12/4/2009

EMERYVILLE, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 51st American Society of Hematology (ASH) Annual Meeting.

The teleconference will begin at 9:00 a.m. CT/10:00 a.m. ET on Monday, December 7, 2009. The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-413-3362 and using the passcode 25914947. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25914947 later in the day. The replay will be available on the Onyx website through January 7, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801 is a targeted alpha-folate inhibi
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014  IRIDEX Corporation ... will release its second quarter 2014 financial results after ... In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... (NYSE MKT: IG), a New Jersey based specialty generic drug ... second quarter ended June 30, 2014. Second Quarter ... in the second quarter of 2014, an increase of 70% ... of $13.3 million for the six months ended June 30, ... 2013 , Total revenues generated from the sale of ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Control, WASHINGTON, Jan. 10 To help ... risks during times,of health crisis, DuPont (NYSE: ... products, DuPont(TM) Corian(R) solid surface, has been selected,by ... The product,recently was incorporated into a children,s ward ...
... South Korea, Jan. 10 Celltrion, Inc., a ... and CSL Limited, Australia,s leading biopharmaceutical,company, announced today ... supply of CSL 360, an experimental monoclonal antibody ... Phase I clinical trials for CSL,360 are currently ...
Cached Medicine Technology:DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody 2
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational partnership that ... and make a difference in the Tampa Bay community. Florida ... provide the support needed to keep the science center moving ... IMAX Dome Theatre from film to a state-of-the-art digital 3D ... in the state of Florida, and it is one of ...
(Date:7/25/2014)... 2014 (HealthDay News) -- The human brain can preserve ... a new study finds. Although dehydration significantly ... have found that the brain compensates by increasing the ... "This research has helped us understand a lot more ... in extreme conditions," study first author Steven Trangmar, a ...
(Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Ibuprofen and Oxcarbazepine Tablets . , The ... and one lot of Oxcarbazepine Tablets, by American Health Packaging ... is used for the treatment of certain types of seizures ... the recall is that Lot #142588, Expiration Date, 01/2016 of ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
(Date:7/25/2014)... 25, 2014 A new study of participants ... which are published today in Cancer , found evidence ... 74 who had an abnormal finding on a lung cancer ... of life than did those who were screened and found ... surprise to the researchers. “We expected that participants with an ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... PHILADELPHIA Researchers have made an important step ... autism spectrum disorders. A researcher collaboration, including geneticists ... and The Children,s Hospital of Philadelphia (CHOP), have ... responsible for neurological development, learning and memory, which ...
... As part of Jani-King International, a worldwide leader in ... to fight swine flu influenza A (H1N1) in schools, ... that the number of reported cases in the United ... from trips to Mexico, many schools have shut down ...
... School explains how and why the swine flu virus is threatening humans ... , ... Boston, MA (Vocus) April 28, 2009 -- A new report from ... threatening humans and describes what to do if the infection reaches your ...
... Barnes of Greenway Medical Technologies and Chairman of HIMSS Electronic Health ... Proper Guidelines for Meaningful EHR UseCARROLLTON, Ga., April 28 ... , A total ... will address key aspects of certified electronic health record (EHR) ...
... FRANCISCO, April 28 DIAKADI Body, Personal ... kick off its summer outdoor workout series, the hottest and ... the month of June, individuals of all fitness levels will ... to take on the DIAKADI way of training! The outdoor ...
... provider of healthcare on-demand patient and staff education, healthcare televisions ... Hospital East, in Louisville, KY. , ... ... -- TeleHealth Services , the nation,s leading provider of ...
Cached Medicine News:Health News:Penn Medicine, CHOP researchers demonstrate first common genetic risk factors for autism 2Health News:Jani-King of Cleveland Ready to Fight Swine Flu 2Health News:Harvard Medical School Releases Special Health Report on Swine Flu 2Health News:Health IT Experts Assemble in Washington D.C. to Present Testimony on Definition of Meaningful Use Before National Committee on Vital and Health Statistics (NCVHS) 2Health News:Health IT Experts Assemble in Washington D.C. to Present Testimony on Definition of Meaningful Use Before National Committee on Vital and Health Statistics (NCVHS) 3Health News:Health IT Experts Assemble in Washington D.C. to Present Testimony on Definition of Meaningful Use Before National Committee on Vital and Health Statistics (NCVHS) 4Health News:SF Outdoor Workout Series: Definitely Not Your Typical Boot Camp! 2Health News:SF Outdoor Workout Series: Definitely Not Your Typical Boot Camp! 3Health News:TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower 2Health News:TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower 3Health News:TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower 4
... In vitro diagnostic reagents for ... (CRP) in human serum as well ... means of particle-enhanced Immunonephelometry using the ... increased levels of a number of ...
Peapod Rongeur, 5.5 length 140 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: